Pomalidomide-PEG1-C2-N3 is primarily utilized in the field of targeted drug delivery and bioconjugation. Its structure allows for the attachment of pomalidomide, a potent immunomodulatory agent, to various biomolecules or drug carriers through the azide (N3) group. This enables precise delivery of the drug to specific cells or tissues, enhancing therapeutic efficacy while minimizing off-target effects. The PEG1 spacer improves solubility and stability, making it suitable for use in aqueous environments. This compound is particularly valuable in cancer therapy, where it can be conjugated to antibodies, nanoparticles, or other targeting moieties to selectively deliver pomalidomide to tumor cells. Additionally, it is employed in research for developing novel drug conjugates and studying mechanisms of action in immunomodulation and cancer treatment.